UCB announced that the U.S. FDA has accepted for review the supplemental Biologics License Application for BIMZELX, an IL-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa. In addition, a second sBLA for the BIMZELX 2mL device presentations has also been accepted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UCBJF:
- UCB downgraded to Hold from Buy at Societe Generale
- UCB upgraded to Equal Weight from Underweight at Morgan Stanley
- UCB price target raised to EUR 130 from EUR 117 at Barclays
- UCB price target raised to EUR 120 from EUR 95 at Berenberg
- UCB price target raised to EUR 125 from EUR 100 at Deutsche Bank